Barry Ticho is the Chief Medical Officer at Stoke Therapeutics and Founder of Verve Therapeutics, bringing over 20 years of experience at the intersection of academic medicine and biotech innovation.
At Stoke, he leads efforts to treat severe diseases by upregulating protein expression with RNA-based medicines. Barry holds an MD-PhD from the University of Chicago and has led clinical development at Moderna, Pfizer, and Biogen. His leadership has driven the advancement of numerous therapeutic programs across diverse disease areas, making him a key figure in translating breakthrough science into impactful medicines.
